首页 › 基金 › Context Capital Management, LLC › ZBIO
Context Capital Management, LLC 对 ZBIO 的持仓历史
ZENAS BIOPHARMA INC · 医疗保健
Context Capital Management, LLC 在 Q3 2026 的 13F 申报中披露持有 ZBIO(ZENAS BIOPHARMA INC)31,050,000 股,市值约 US$39.7M,约占其申报组合的 1.32%,在其申报持仓中市值排名第 29 位。 Context Capital Management, LLC 最近 3 个申报季度中有 3 个季度披露了 ZBIO 持仓,最早可追溯至 Q1 2026。
最后更新: 2026-11-13 · 来源: SEC EDGAR Form 13F-HR
Context Capital Management, LLC 对 ZBIO 的持仓演变
Context Capital Management, LLC 于 Q1 2026 首次披露 ZBIO 持仓:29,100,000 股(约 US$30.1M)。 该持仓在 Q2 2026 达到峰值 35,800,000 股,市值约 US$42.6M。 在 3 次申报中,Context Capital Management, LLC 1 次增持、1 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 31,050,000 股、市值约 US$39.7M,环比减持 -4,750,000 股。。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q1 2026 | 29.10M | $30.12M | 新进 |
| Q2 2026 | 35.80M | $42.60M | 增持 |
| Q3 2026 | 31.05M | $39.70M | 减持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 ZBIO 与 13F 数据
ZBIO(ZENAS BIOPHARMA INC)属于医疗保健行业。我们追踪的基金中还有 62 只申报持有 ZBIO,申报仓位最大的包括:SR ONE CAPITAL MANAGEMENT, LP (US$127.9M), NEA Management Company, LLC (US$102.1M), Enavate Sciences GP, LLC (US$99.5M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 ZBIO 的基金
- SR ONE CAPITAL MANAGEMENT, LP 5.04M 股 · $127.86M · Q2 2026
- NEA Management Company, LLC 4.02M 股 · $102.11M · Q2 2026
- Enavate Sciences GP, LLC 3.92M 股 · $99.47M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 67.20M 股 · $80.32M · Q2 2026
- Royalty Pharma Sub-Manager, LLC 2.39M 股 · $60.61M · Q2 2026
- Fairmount Funds Management LLC 2.36M 股 · $59.87M · Q2 2026
- NVP Associates, LLC 1.84M 股 · $46.66M · Q2 2026
- EcoR1 Capital, LLC 789.50K 股 · $20.04M · Q2 2026
- ArrowMark Colorado Holdings LLC 573.32K 股 · $14.55M · Q2 2026
- Rock Springs Capital Management LP 502.08K 股 · $12.74M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 490.77K 股 · $12.46M · Q2 2026
- NEXTBio Capital Management LP 426.74K 股 · $11.51M · Q3 2026
更多关于 Context Capital Management, LLC
常见问题
How long has Context Capital Management, LLC held ZBIO?
Context Capital Management, LLC has disclosed ZBIO holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Context Capital Management, LLC's current position in ZBIO?
As of Q3 2026, Context Capital Management, LLC holds 31.05M shares of ZBIO (ZENAS BIOPHARMA INC), valued at $39.70M, representing 1.32% of its reported portfolio and ranking #29.
Has Context Capital Management, LLC been buying or selling ZBIO?
In the latest 13F filing (Q3 2026), Context Capital Management, LLC reduced its position in ZBIO. The position peaked in Q2 2026 at 35.80M shares.
Which other funds hold ZBIO?
Other major institutional holders of ZBIO include SR ONE CAPITAL MANAGEMENT, LP, NEA Management Company, LLC, Enavate Sciences GP, LLC, among 62 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.